Corporate Partnerships
OraSure Technologies has partnerships with various diagnostic and pharmaceutical companies. The Company’s current partnerships include:
Schering-Plough Corporation
Schering-Plough Corporation, a worldwide leader in the discovery and development of novel HCV therapies, and OraSure Technologies are currently collaborating on the development and promotion of the OraQuick® HCV test, a rapid point-of-care test for the detection of the Hepatitis C virus in oral fluid, fingerstick blood, venous whole blood, plasma and serum. In October 2008, OraSure submitted a pre-market approval application to the U.S. Food and Drug Administration ("FDA") for the OraQuick® HCV test. Learn More »
Roche Diagnostics
Roche Diagnostics and OraSure Technologies are currently collaborating on the development and commercialization of homogeneous fully-automated oral fluid drugs of abuse assays that can run on random access chemistry analyzers. The oral fluid assays are being developed for use with OraSure's Intercept® Oral Specimen Collection Device and Roche's KIMS (kinetic interaction of microparticles in solution) technology. The oral fluid assays will be designed to run on various automated analyzers and to allow oral fluid samples to be processed with the same efficiency as current urine based tests. Learn More »
The information provided on this website is intended only for the residents of the United States. The products discussed herein may have different labeling in different countries and may not be for sale in all other countries.
Page last updated: March 15, 2009
